Solid-phase phosphoramidite chemistry
in oligo synthesis

Oligonucleotide synthesizers automate solid-phase phosphoramidite chemistry through iterative detritylation, coupling, capping and oxidation cycles, enabling the high-fidelity synthesis of DNA and RNA oligonucleotides. Modern platforms support a broad range of phosphoramidite building blocks and modification chemistries, facilitating the production of primers, probes, long oligonucleotides and specialised sequences for molecular diagnostics, genomics, synthetic biology and therapeutic development. Following synthesis, oligonucleotides undergo deprotection, cleavage and downstream purification prior to quality control and application-specific use.

Key considerations for establishing in-house oligo manufacturing

Organisations evaluating in-house oligonucleotide synthesis should assess throughput requirements, synthesis scale, laboratory infrastructure, reagent management, waste handling procedures and automation needs. Instrument selection should also consider modification requirements, workflow flexibility and anticipated future growth. Access to high-quality phosphoramidites, reagents, consumables and technical support is critical for maintaining consistent synthesis performance and product quality. Additional considerations include support for modified oligonucleotide chemistries, reagent compatibility, production scalability and integration with existing quality management processes.

Advantages of configurable oligo
synthesis platforms

Modern oligo synthesis platforms provide greater control over production scheduling, sequence confidentiality, turnaround time and quality management. Configurable instruments can be adapted to changing throughput demands and specialised applications while supporting a broad range of synthesis chemistries and oligonucleotide modifications. When combined with a complete oligo synthesis ecosystem, including phosphoramidites, synthesis reagents, columns and consumables, in-house capabilities can improve supply continuity, accelerate development timelines and support long-term manufacturing scalability.

Build in-house oligonucleotide
synthesis capabilities

Explore the principles of oligonucleotide synthesis, key considerations for implementing in-house manufacturing, and how configurable synthesis platforms support scalability, quality and operational efficiency.